A Randomized Controlled Trial to Evaluate Allopurinol Versus Placebo on Left Ventricular Mass in Living Kidney Donors
Kidney360 · 2026-10 · 7 (10) · 2363-2371
DOI: 10.34067/kid.0000001313 ↗Abstract
Key Points Donation of a kidney is regarded safe, although it may be associated with increased long-term cardiovascular risks. This is the first study to evaluate if allopurinol has any benefits on left ventricular mass, ambulatory BP, and insulin resistance in kidney donors. We found no clinically relevant positive impact of 9 months of allopurinol treatment on cardiovascular risk factors in living kidney donors. Background Living kidney donation is regarded safe, although recent studies raise concern on long-term cardiovascular risks, including left ventricular mass (LVM) and hypertension, resulting in higher cardiovascular mortality. Elevated uric acid has been associated with higher LVM. We therefore hypothesized that lowering uric acid can reduce LVM in living kidney donors. Methods The study was a single-center, phase 2b efficacy, 1:1 randomized, double-blind, placebo-controlled trial over 9 months. Participants ( n =71) were healthy kidney donors aged 18+ years with eGFR >30 ml/min per 1.73 m 2 examined ≥6 months after donor nephrectomy. The intervention consisted of allopurinol 300 mg or placebo once daily for 9 months, and the main outcome was change in LVM from baseline to month 9 in the allopurinol group compared with placebo, evaluated by the use of cardiac magnetic resonance imaging. Results Uric acid levels were significantly lower in the allopurinol group ( P < 0.001). We found no significant differences between the changes in magnetic resonance imaging–estimated LVM between the treatment groups. The mean changes were −0.25 (±4.4) g in the allopurinol group and 1.04 (±4.2) g in the placebo group ( P = 0.25). There was no effect of allopurinol on BP ( P = 0.98) or indexes of insulin sensitivity ( P = 0.62). Adverse events occurred in 28 (39%) participants, 18 (70%) in the allopurinol group and ten (37%) in the placebo group. Three events were considered severe, all in the allopurinol group. Conclusions We found no effects on LVM, BP, or insulin sensitivity of 9 months of allopurinol treatment in living kidney donors, despite a significant effect on uric acid. Clinical Trial registry name and registration number: NCT03353298.
EUVIMED